

Evan Diamond

Partner

Trial and Global Disputes / Intellectual Property

New York: +1 212 556 2297
ediamond@kslaw.com



Evan Diamond is a partner on our Intellectual Property, Patent, Trademark and Copyright Litigation team. Evan focuses his practice on patent litigation matters, with an emphasis on the pharmaceutical and biotechnology industries. In federal court trials, *inter partes* reviews before the Patent Trial and Appeal Board, and appeals before the Federal Circuit, he has substantial experience representing pharmaceutical and life sciences technology companies through trial victory or to favorable business resolutions for products with hundreds of millions or billions of dollars in annual sales.

Evan has been acknowledged by IAM Patent 1000 as one of the "World's Leading Patent Professionals," and has been recognized for the past five years as a "Top Ranked Intellectual Property Litigation Attorney" and a "Rising Star" by Super Lawyers. Evan speaks and writes extensively on new developments impacting life sciences patents and business concerns for the industry.

Evan brings to his practice a technical background in chemistry and biochemistry, having received an M.S. from the University of Pennsylvania prior to entering the legal field.

Matters

In the first three Final Written Decisions for inter partes reviews in the Hatch-Waxman context, obtained rulings from the PTAB for client Galderma upholding all challenged claims on patents covering Oracea®, a multi-million dollar drug for the treatment of rosacea

Obtained preliminary injunction and then permanent injunction against launch of a generic version of Oracea®, which was upheld by the Federal Circuit on appeal

Obtained favorable claim construction in second-filer Hatch-Waxman litigation regarding Oracea®, resulting in withdrawal of Paragraph IV challenge before trial

Obtained decision upholding validity of key patent in bench trial in District of New Jersey regarding Hatch-Waxman dispute for Merck's drug Emend® for Injection, for nausea and vomiting due to highly emetogenic chemotherapy

regarding Lexapro® (Forest Labs and Lundbeck), Namenda® (Forest Labs and Merz), Targretin® (Eisai and Valeant), and Amitiza® (Sucampo)

Credentials

EDUCATION

J.D., Harvard University, cum laude

B.A., University of Pennsylvania, summa cum laude, Phi Beta Kappa

M.S. in Biochemistry, University of Pennsylvania

ADMISSIONS

U.S. Court of Appeals for the Federal Circuit

New York

ASSOCIATIONS

Federal Circuit Bar Association

PTAB Bar Association

Member of the New York Intellectual Property Law Association, New Jersey Intellectual Property Law

Recognition

Super Lawyers Rising Stars

2015-2017

Insights

ARTICLE

September 1, 2021 • Source: Intellectual Property & Technology Law Journal

“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What Is Required, and What to Expect?

CLIENT ALERT

June 7, 2021

Update on the Proposed TRIPS Waiver at the WTO: Where is it Headed, and What to Expect?

April 7, 2021

“Purple Book” Patent Listing Under Biological Product Patent Transparency Act: What is Required, and What to Expect?

[VIEW ALL ON KSLAW.COM](#)

Events

SPEAKING ENGAGEMENT

April 27, 2021

Vanessa Yen, Evan Diamond, Gerald Flattmann to Speak at American Conference Institute’s 2021 Paragraph IV Disputes Master Symposium

WEBINAR

November 9, 2021

King & Spalding Pharmaceutical University 2021

[VIEW ALL ON KSLAW.COM](#)

News

IN THE NEWS

July 18, 2022 • Source: Law360

Vanessa Yen and Evan Diamond represent cancer research institutions in U.S. Supreme Court amicus briefing on closely-watched patent issues

July 1, 2022 • Source: Law360

Steven Zager, Gerald Flattmann, Vanessa Yen and Evan Diamond counsel GW Pharmaceuticals before the Federal Circuit in a patent infringement dispute

January 6, 2022 • Source: Law360

Evan Diamond discusses the infringement law for skinny labels

[VIEW ALL ON KSLAW.COM](#)